Illumina and NVIDIA collaborate to decode biology and propel precision health

Partnership Overview - Illumina and NVIDIA are collaborating to combine AI advancements with multiomic data at scale, leveraging Illumina's sequencing technology and NVIDIA's AI tools to accelerate drug discovery and clinical development [1][8] - The partnership aims to integrate NVIDIA's RAPIDS™ accelerated data science software, BioNeMo™ platform, and MONAI for spatial cell imaging workflows with Illumina's Connected Analytics platform [2] - The collaboration will enable DRAGEN algorithms on NVIDIA GPUs and incorporate NVIDIA's image processing and single-cell tertiary analysis tools into Illumina's multiomics module [3] Technological Integration - Illumina's DRAGEN-powered multiomics offerings, genomics AI tools, and Connected Analytics platform have streamlined genomic data generation and analysis [10] - NVIDIA's AI and data science tools will be integrated with Illumina's sequencing and analytics platforms to drive the next generation of genomics interpretation [3] - Customers will be able to leverage NVIDIA's biology foundation models with their proprietary datasets for tasks such as cell state or gene transcription prediction [5] Industry Impact - The collaboration aims to democratize genomics for drug discovery through AI-powered insights, enabling deeper biological insights and total workflow solutions for customers [3] - The partnership is expected to advance technology platforms for the analysis and interpretation of multiomic data, accelerating progress in clinical research and genomics AI development [8] - Illumina's investment in AI for genomic interpretation includes leading algorithms such as SpliceAI, PrimateAI-3D, and Emedgene xAI [10]